Please login to the form below

Not currently logged in
Email:
Password:

Anish Mehta appointed CEO of new women's health business

Will head up the former Teva portoflio CVC Capital Partners recently acquired

Anish MehtaLondon-based investment firm CVC Capital Partners has appointed Anish Mehta as chief executive officer of the international women’s health assets portfolio it acquired from Teva Pharmaceuticals last month.

Mehta joins from Allergan, where he was head of international business development leading the team responsible for corporate development and licensing activity in support of the international business.

He said: “I am honoured to have this opportunity to partner with CVC and the existing team to lead this exciting new business.

The combination of high quality products and a talented team creates a unique opportunity for us to build a leading, global, speciality pharmaceutical business dedicated to women’s health.”

Prior to his new role, Mehta has served at Actavis, taking the helm of its European and Middle East business, where he managed a portfolio of pharmaceutical products.

Cathrin Petty, partner and head of European Healthcare, CVC, said: “Anish is a well-established industry veteran, having spent over 20 years in the global healthcare space.

“His deep experience in M&A, complex carve outs and building businesses will be invaluable to us as we look to scale this business.”

19th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics